MetaCap

AnaptysBio (ANAB) vs Nuvation Bio (NUVB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

AnaptysBio (ANAB) has outperformed Nuvation Bio (NUVB) over the past year, gaining 76.6% versus a loss of 45.6%. Over five years, ANAB leads with a +124.8% price change compared with -53.5% for NUVB. AnaptysBio is the larger company by market cap ($1.39 billion vs $1.34 billion), about 1.0 times the size, while Nuvation Bio is growing revenue faster (+699.0% vs +157.0%).

AnaptysBio converts more of its revenue into profit, with a net margin of -5.6% versus -325.3%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ANAB+76.58%NUVB-45.64%
+175%+59%-56%
Nov 21, 20251 yearNov 20, 2026
ANAB+127.09%NUVB-58.01%
+254%+74%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ANAB versus NUVB key metrics
MetricANABNUVB
Share price$46.63$3.80
Market cap$1.39B$1.34B
1-day change-1.62%-0.26%
YTD return+44.28%-57.59%
1-year return+76.58%-45.64%
5-year return+124.76%-53.49%
P/E ratio (TTM)7.15—
Forward P/E8.66—
EPS (TTM)$6.52$-0.39
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$234.60M$62.90M
Revenue growth (YoY)+157.01%+698.96%
Net income (latest FY)$-13.23M$-204.63M
Operating margin96.72%-338.72%
Net margin-5.64%-325.31%
52-week high$72.36$9.75
52-week low$26.01$3.71
Distance from 52-week high-35.56%-61.03%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+87.11%+227.63%
Average volume496.92K5.24M
Shares outstanding29.73M352.02M
Employees—310
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ANAB has outperformed NUVB by 122.2 percentage points over the past year.
  • AnaptysBio is more profitable, keeping -5.6 cents of every revenue dollar as net income versus -325.3 cents for Nuvation Bio.
  • Nuvation Bio grew revenue faster in its latest fiscal year (+698.96% vs +157.01%).

About AnaptysBio

ANAB stock →

AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations

About Nuvation Bio

NUVB stock →

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 310 employees

ANAB vs NUVB FAQ

Which is bigger, AnaptysBio or Nuvation Bio?

AnaptysBio (ANAB) is larger, with a market capitalization of $1.39B compared with $1.34B for Nuvation Bio (NUVB).

Which stock has performed better over the past year, ANAB or NUVB?

ANAB returned +76.58% over the past 12 months, compared with -45.64% for NUVB (price return, excluding dividends). Past performance does not predict future results.

Are AnaptysBio and Nuvation Bio in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons